{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:46Z","timestamp":1792404046192,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clinbiochem.2021.01.012","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:56:33Z","timestamp":1612274193000},"page":"40-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS\/MS method"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-5718","authenticated-orcid":false,"given":"Makoto","family":"Kai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ohchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2021.01.012_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","article-title":"Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria","volume":"54","author":"Mauldin","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.130.3.787","article-title":"Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia","volume":"130","author":"Beardsley","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0015","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2165\/00003495-200363200-00001","article-title":"Appropriate empirical antibacterial therapy for nosocomial infections","volume":"63","author":"Kollef","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0020","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01252-07","article-title":"In vivo pharmacodynamic profiling of doripenem against","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0030","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/jac\/dkx149","article-title":"Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens","volume":"72","author":"Taubert","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0035","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2018.03.008","article-title":"Population pharmacokinetics of daptomycin in critically ill patients","volume":"52","author":"Soraluce","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0045","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0050","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1345\/aph.1C419","article-title":"Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials","volume":"37","author":"Schentag","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/428053","article-title":"Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"41","author":"Wispelwey","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0060","first-page":"991","article-title":"Pharmacokinetics and pharmacodynamics in the development of antifungal compounds","volume":"4","author":"Andes","year":"2003","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0070","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00134-015-4032-6","article-title":"Understanding PK\/PD","volume":"42","author":"Roberts","year":"2016","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0075","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2334-14-288","article-title":"How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0085","first-page":"3178","article-title":"Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for?","volume":"70","author":"Huttner","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0004563215618981","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"53","author":"Balakrishnan","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchromb.2013.04.036","article-title":"First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma","volume":"930","author":"Sousaa","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jchromb.2012.09.016","article-title":"A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection","volume":"907","author":"Briscoea","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FTD.0000000000000570","article-title":"Simultaneous quantification of nine antimicrobials by LC-MS\/MS for therapeutic drug monitoring in critically ill patients","volume":"41","author":"Neugebauer","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2018.05.015","article-title":"Liquid chromatography-tandem mass spectrometry for the quantification of moxifloxacin, ciprofloxacin, daptomycin, caspofungin, and isavuconazole in human plasma","volume":"157","author":"H\u00f6sla","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpba.2019.01.039","article-title":"A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM","volume":"169","author":"Zoua","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jchromb.2008.03.001","article-title":"Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection","volume":"867","author":"Ikeda","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpba.2018.01.031","article-title":"Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC\u2013MS\/MS method","volume":"152","author":"Paal","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00216-010-3639-2","article-title":"Daptomycin determination by liquid chromatography\u2013mass spectrometry in peritoneal fluid, blood plasma, and urine of clinical patients receiving peritoneal dialysis treatment","volume":"397","author":"Gika","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0135","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jchromb.2010.06.038","article-title":"Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography\u2013tandem mass spectrometry","volume":"878","author":"Fanga","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","article-title":"Fast and simple LC\u2013MS\/MS method for quantifying plasma voriconazole","volume":"413","author":"Pauwels","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0150","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpba.2009.03.034","article-title":"A high\u2013throughput LC\u2013MS\/MS method for the quantitation of posaconazole in human plasma: Implementing fused core silica liquid chromatography","volume":"50","author":"Cunliffe","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0160","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ ucm070107.pdf, (2018) (accessed June 18th, 2020)."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijid.2017.01.017","article-title":"Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures","volume":"57","author":"Ogami","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/chromsci\/bmy114","article-title":"A validated ultra-performance liquid chromatography tandem triple quadrupole mass spectrometric method for fast determination of losartan in rabbit plasma","volume":"57","author":"Alam","year":"2019","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jchromb.2016.05.049","article-title":"Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing","volume":"1027","author":"Witt","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10047-019-01139-x","article-title":"Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: in vitro studies","volume":"2","author":"Onichimowski","year":"2020","journal-title":"J. Artif. Organs"},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.ackd.2017.05.004","article-title":"Antibiotic dosing in continuous renal replacement therapy","volume":"24","author":"Shaw","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.clinbiochem.2021.01.012_b0190","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1248\/bpb.b17-00008","article-title":"Pharmacokinetic\/pharmacodynamic analysis for doripenem regimens in intensive care unit patient","volume":"40","author":"Tanaka","year":"2017","journal-title":"Biol. Pharm. Bull."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:56:22Z","timestamp":1757865382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912021000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":38,"alternative-id":["S0009912021000291"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.01.012","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS\/MS method","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}